Informational letter to healthcare professionals regarding the medicinal product Victoza® (liraglutide). Recommendations for switching patients to other medicinal products in connection with the gradual withdrawal of Victoza® manufactured by Novo Nordisk A/S from the market.

28.07.2026 237 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу Віктоза® (ліраглутид). Рекомендації переведення пацієнтів на інші лікарські засоби у зв’язку із поступовим виведенням з ринку Віктоза® виробництва А/Т Ново НордіскPDF · 611 КБ

Завантажити

Informational letter to healthcare professionals regarding the medicinal product Victoza® (liraglutide). Recommendations for switching patients to other medicinal products in connection with the gradual withdrawal of Victoza® manufactured by Novo Nordisk A/S from the market.

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Informational letter to healthcare professionals regarding the medicinal product Victoza® (liraglutide). Recommendations for switching patients to other medicinal products in connection with the gradual withdrawal of Victoza® manufactured by Novo Nordisk A/S from the market.

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration